These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 23613107

  • 41. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 42. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 43. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
    Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ.
    Leukemia; 2005 Jul 12; 19(7):1198-206. PubMed ID: 15902298
    [Abstract] [Full Text] [Related]

  • 44. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB.
    Oncogene; 2010 May 20; 29(20):2962-72. PubMed ID: 20228846
    [Abstract] [Full Text] [Related]

  • 45. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 20; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 46. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R, Gandhi V, Plunkett W.
    Cancer Res; 2006 Nov 15; 66(22):10959-66. PubMed ID: 17108134
    [Abstract] [Full Text] [Related]

  • 47. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
    Luo X, Feng M, Zhu X, Li Y, Fei J, Zhang Y.
    Hematology; 2013 Nov 15; 18(6):334-40. PubMed ID: 24129092
    [Abstract] [Full Text] [Related]

  • 48. [Inhibitory effect of alantolactone on the proliferation of K562/ADR cells and its mechanism].
    Yang C, Cai H, Yan J, Yang J, Sun M, Meng X, Ma T.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun 15; 35(6):515-8. PubMed ID: 24985175
    [Abstract] [Full Text] [Related]

  • 49. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS, Kim MJ, Bae JH, Song HS, Chung BS, Lee MK, Kang CD, Lee HS, Kim DW, Kim SH.
    Cancer Lett; 2007 Jul 08; 252(1):75-85. PubMed ID: 17223257
    [Abstract] [Full Text] [Related]

  • 50. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.
    Stem Cells; 2003 Jul 08; 21(3):315-21. PubMed ID: 12743326
    [Abstract] [Full Text] [Related]

  • 51. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):791-9. PubMed ID: 25449787
    [Abstract] [Full Text] [Related]

  • 52. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.
    Int J Oncol; 2011 Sep 28; 39(3):585-91. PubMed ID: 21637917
    [Abstract] [Full Text] [Related]

  • 53. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC, Elzinga BM, O'Sullivan GC, McKenna SL.
    Am J Hematol; 2011 Jan 28; 86(1):38-47. PubMed ID: 21132731
    [Abstract] [Full Text] [Related]

  • 54. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P.
    Carcinogenesis; 2014 May 28; 35(5):1132-43. PubMed ID: 24445143
    [Abstract] [Full Text] [Related]

  • 55. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 56. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.
    Am J Hematol; 2013 May 07; 88(5):385-93. PubMed ID: 23420553
    [Abstract] [Full Text] [Related]

  • 57. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.
    Cancer Lett; 2015 May 01; 360(2):245-56. PubMed ID: 25697481
    [Abstract] [Full Text] [Related]

  • 58. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 59. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y, Rahmani M, Pei XY, Dent P, Grant S.
    Blood; 2004 Jul 15; 104(2):509-18. PubMed ID: 15039284
    [Abstract] [Full Text] [Related]

  • 60. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 15; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.